| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 302.42 KB | Adobe PDF |
Advisor(s)
Abstract(s)
This study aims to assess prevalence and pregnancy outcome for sex chromosome trisomies (SCTs) diagnosed prenatally or in
the first year of life. Data held by the European Surveillance of Congenital Anomalies (EUROCAT) database on SCT cases
delivered 2000–2005 from 19 population-based registries in 11 European countries covering 2.5 million births were analysed.
Cases included were livebirths diagnosed to 1 year of age, fetal deaths from 20 weeks gestation and terminations of pregnancy
for fetal anomaly (TOPFA). In all, 465 cases of SCT were diagnosed between 2000 and 2005, a prevalence of 1.88 per 10,000
births (95% CI 1.71–2.06). Prevalence of XXX, XXY and XYY were 0.54 (95% CI 0.46–0.64), 1.04 (95% CI 0.92–1.17) and
0.30 (95% CI 0.24–0.38), respectively. In all, 415 (89%) were prenatally diagnosed and 151 (36%) of these resulted in
TOPFA. There was wide country variation in prevalence (0.19–5.36 per 1000), proportion prenatally diagnosed (50–100%)
and proportion of prenatally diagnosed resulting in TOPFA (13–67%). Prevalence of prenatally diagnosed cases was higher in
countries with high prenatal detection rates of Down syndrome. The EUROCAT prevalence rate for SCTs diagnosed prenatally or
up to 1 year of age represents 12% of the prevalence expected from cytogenetic studies of newborn babies, as the majority of
cases are never diagnosed or are diagnosed later in life. There is a wide variation between European countries in prevalence,
prenatal detection and TOPFA proportions, related to differences in screening policies as well as organizational and cultural
factors.
Description
EUROCAT Working group collaborator: Carlos Dias
Keywords
Sex Chromosome Trisomies Prenatal Diagnosis Termination of Pregnancy Estados de Saúde e de Doença RENAC
Pedagogical Context
Citation
Eur J Hum Genet. 2011 Feb;19(2):231-4. Epub 2010 Aug 25
